| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Department of Laboratory Medicine, Children’s Hospital,
2
Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine, and
3
Cardiovascular Diseases, Brigham and Women’s Hospital, and Departments of
4
Pathology and
5
Medicine, Harvard Medical School, Boston, MA 02115.
a Address correspondence to this author at: Children’s Hospital, Department of Laboratory Medicine, 300 Longwood Ave., Boston, MA 02115. Fax 617-713-4347; e-mail rifai{at}tch.harvard.edu.
Background: Coronary heart disease remains the leading cause of morbidity and mortality in the industrialized world. Clinical and laboratory studies have shown that inflammation plays a major role in the initiation, progression, and destabilization of atheromas. C-Reactive protein (CRP), an acute phase reactant that reflects low-grade systemic inflammation, has been studied in a variety of cardiovascular diseases.
Approach: Findings from prospective clinical trials were examined to determine the prognostic utility of CRP in acute coronary syndromes, and observations from epidemiological studies were reviewed to determine the ability of CRP to predict future first coronary events. The analytical considerations of CRP measurement in these clinical applications were also examined.
Content: In patients with established coronary disease, CRP has been shown to predict adverse clinical events. In addition, prospective studies have consistently shown that CRP is a strong predictor of future coronary events in apparently healthy men and women. The relative risk associated with CRP is independent of other cardiovascular disease risk factors. High-sensitivity CRP (hs-CRP) assays are needed for risk assessment of cardiovascular disease. Such assays are currently available but may require further standardization because patients’ results will be interpreted using population-based cutpoints. Preventive therapies to attenuate coronary risk in individuals with increased hs-CRP concentrations include aspirin and statin-type drugs.
Summary: hs-CRP has prognostic utility in patients with acute coronary syndromes and is a strong independent predictor of future coronary events in apparently healthy subjects.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  A. Sarandol, S. Kirli, C. Akkaya, N. Ocak, E. Eroz, and E. Sarandol Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment J Psychopharmacol, November 1, 2007; 21(8): 857 - 863. [Abstract] [PDF]
|
|
|
|
 |
|
 G. M. Connolly, R. Cunningham, A. P. Maxwell, and I. S. Young Decreased Serum Retinol Is Associated with Increased Mortality in Renal Transplant Recipients Clin. Chem., October 1, 2007; 53(10): 1841 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Patel, C. A. King, S. R. Bailey, J. W. Holt, K. Venkatachalam, A. Agrawal, A. J. Valente, and B. Chandrasekar Interleukin-17 Stimulates C-reactive Protein Expression in Hepatocytes and Smooth Muscle Cells via p38 MAPK and ERK1/2-dependent NF-{kappa}B and C/EBPbeta Activation J. Biol. Chem., September 14, 2007; 282(37): 27229 - 27238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C.P. Franco, E. M.S. Higa, V. D'Almeida, F. G. de Sousa, A. L. Sawaya, Z. B. Fortes, and R. Sesso Homocysteine and Nitric Oxide Are Related to Blood Pressure and Vascular Function in Small-for-Gestational-Age Children Hypertension, August 1, 2007; 50(2): 396 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Kapoor, S Clarke, R Stanworth, K S Channer, and T H Jones The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes Eur. J. Endocrinol., May 1, 2007; 156(5): 595 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ramzy, V. Rao, L. C. Tumiati, N. Xu, R. Sheshgiri, J. Jackman, D. H. Delgado, and H. J. Ross Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1137 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Song, T. Y Li, R. M van Dam, J. E Manson, and F. B Hu Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women Am. J. Clinical Nutrition, April 1, 2007; 85(4): 1068 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Kilic, D Ural, E Ural, Z Yumuk, A Agacdiken, T Sahin, G Kahraman, G Kozdag, A Vural, and B Komsuoglu Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome Heart, August 1, 2006; 92(8): 1041 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. AbuMweis, C. A. Vanstone, N. Ebine, A. Kassis, L. M. Ausman, P. J. H. Jones, and A. H. Lichtenstein Intake of a Single Morning Dose of Standard and Novel Plant Sterol Preparations for 4 Weeks Does Not Dramatically Affect Plasma Lipid Concentrations in Humans J. Nutr., April 1, 2006; 136(4): 1012 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Wu and L. L. Wu Association of Soluble Markers with Various Stages and Major Events of Atherosclerosis Ann. Clin. Lab. Sci., January 1, 2005; 35(3): 240 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rej Clinical Chemistry through Clinical Chemistry: A Journal Timeline Clin. Chem., December 1, 2004; 50(12): 2415 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Suarez C-Reactive Protein Is Associated With Psychological Risk Factors of Cardiovascular Disease in Apparently Healthy Adults Psychosom Med, September 1, 2004; 66(5): 684 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kluft Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C21 - C27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Aso, K.-i. Okumura, T. Inoue, R. Matsutomo, N. Yoshida, S. Wakabayashi, K. Takebayashi, and T. Inukai Results of Blood Inflammatory Markers Are Associated More Strongly With Toe-Brachial Index Than With Ankle-Brachial Index in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1381 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Block, C. Jensen, M. Dietrich, E. P. Norkus, M. Hudes, and L. Packer Plasma C-Reactive Protein Concentrations in Active and Passive Smokers: Influence of Antioxidant Supplementation J. Am. Coll. Nutr., April 1, 2004; 23(2): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fonseca, C. Desouza, S. Asnani, and I. Jialal Nontraditional Risk Factors for Cardiovascular Disease in Diabetes Endocr. Rev., February 1, 2004; 25(1): 153 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, S.-P. Zhao, Y.-C. Cheng, and Y.-L. Li Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease Clin. Chem., August 1, 2003; 49(8): 1347 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Dzau Risk assessment in cardiovascular disease: from traditional risk factors to genomics Eur. Heart J. Suppl., August 1, 2003; 5(suppl_F): F48 - F55. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Koenig C-reactive protein and cardiovascular risk: an update on what is going on in cardiology Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1039 - 1041. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Huittinen, M. Leinonen, L. Tenkanen, H. Virkkunen, M. Manttari, T. Palosuo, V. Manninen, and P. Saikku Synergistic Effect of Persistent Chlamydia pneumoniae Infection, Autoimmunity, and Inflammation on Coronary Risk Circulation, May 27, 2003; 107(20): 2566 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Tsen, G.-Y. Kao, C.-L. Chang, F.-Y. Lai, C.-H. Huang, S. Ouyang, M.-H. Yu, C.-P. Wang, and Y-N. Chiou Evaluation and Validation of a Duck IgY Antibody-based Immunoassay for High-Sensitivity C-reactive Protein: Avian Antibody Application in Clinical Diagnostics Clin. Chem., May 1, 2003; 49(5): 810 - 813. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Kimberly, H. W. Vesper, S. P. Caudill, G. R. Cooper, N. Rifai, F. Dati, and G. L. Myers Standardization of Immunoassays for Measurement of High-Sensitivity C-reactive Protein. Phase I: Evaluation of Secondary Reference Materials Clin. Chem., April 1, 2003; 49(4): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Beaudeux, L. Burc, F. Imbert-Bismut, P. Giral, M. Bernard, E. Bruckert, and M. J. Chapman Serum Plasma Pregnancy-Associated Protein A: A Potential Marker of Echogenic Carotid Atherosclerotic Plaques in Asymptomatic Hyperlipidemic Subjects at High Cardiovascular Risk Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): e7 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Jenny, R. P. Tracy, M. S. Ogg, L. A. Luong, L. H. Kuller, A. M. Arnold, A. R. Sharrett, and S. E. Humphries In the Elderly, Interleukin-6 Plasma Levels and the -174G>C Polymorphism Are Associated With the Development of Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 2066 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Middleton Effect of Analytical Error on the Assessment of Cardiac Risk by the High-Sensitivity C-Reactive Protein and Lipid Screening Model Clin. Chem., November 1, 2002; 48(11): 1955 - 1962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sternik, S. Samee, H. V. Schaff, K. J. Zehr, L. O. Lerman, D. R. Holmes, J. Herrmann, and A. Lerman C-Reactive Protein Relaxes Human Vessels In Vitro Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1865 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Futterman and L. Lemberg High-Sensitivity C-Reactive Protein Is the Most Effective Prognostic Measurement of Acute Coronary Events Am. J. Crit. Care., September 1, 2002; 11(5): 482 - 486. [Full Text] [PDF]
|
|
|
|
|
|
R. Hayaishi-Okano, Y. Yamasaki, N. Katakami, K. Ohtoshi, S.-I. Gorogawa, A. Kuroda, M. Matsuhisa, K. Kosugi, N. Nishikawa, Y. Kajimoto, et al. Elevated C-Reactive Protein Associates With Early-Stage Carotid Atherosclerosis in Young Subjects With Type 1 Diabetes Diabetes Care, August 1, 2002; 25(8): 1432 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ishibashi, Y. Takemura, H. Ishida, K. Watanabe, and T. Kawai C-Reactive Protein Kinetics in Newborns: Application of a High-Sensitivity Analytic Method in Its Determination Clin. Chem., July 1, 2002; 48(7): 1103 - 1106. [Full Text] [PDF]
|
|
|
|
|
|
M. K.C. Ng, P. Y. Liu, A. J. Williams, S. Nakhla, L. P. Ly, D. J. Handelsman, and D. S. Celermajer Prospective Study of Effect of Androgens on Serum Inflammatory Markers in Men Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1136 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Chan, G. F. Watts, P. H. R. Barrett, L. J. Beilin, and T. A. Mori Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity Clin. Chem., June 1, 2002; 48(6): 877 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Byrne, I A Jagroop, H E Montgomery, M Thomas, D P Mikhailidis, N G Milton, and A F Winder Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk J. Clin. Pathol., April 1, 2002; 55(4): 280 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Kuuliala, K Eberhardt, A Takala, H Kautiainen, H Repo, and M Leirisalo-Repo Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study Ann Rheum Dis, March 1, 2002; 61(3): 242 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rothkrantz-Kos, M. P.J. Schmitz, O. Bekers, P. P.C.A. Menheere, and M. P. van Dieijen-Visser High-Sensitivity C-Reactive Protein Methods Examined Clin. Chem., February 1, 2002; 48(2): 359 - 362. [Full Text] [PDF]
|
|
|
|
|
|
J. Nilsson, M.P.S. Ares, M. Lindholm, G.N. Fredriksonl, and S. Jovinge Inflammation and cholesterol Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A18 - A25. [Abstract] [PDF]
|
|
|
|
|
|
R. A. Hegele, M. R. Ban, and T. K. Young Serum C-Reactive Protein in Canadian Inuit and Its Association with Genetic Variation on Chromosome 1q21 Clin. Chem., September 1, 2001; 47(9): 1707 - 1709. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Ayash Re: Europium nanoparticles and time-resolved fluorescence for ultrasensitive detection of prostate-specific antigen. Clin. Chem., September 1, 2001; 47(9): 1743 - 1744. [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
